Rilimogene galvacirepvec-rilimogene glafolivec

Drug Profile

Rilimogene galvacirepvec-rilimogene glafolivec

Alternative Names: PROSTVAC; PROSTVAC-V-PROSTVAC-F; PROSTVAC-VF-TRICOM; PSA-TRICOM; Recombinant vaccinia virus vaccine (PROSTVAC-V/F) - BN ImmunoTherapeutics; Rilimogene gamvacirepvec-rilimogene glafolivec; Vaccinia PSA TRICOM-fowlpox PSA TRICOM

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator National Cancer Institute (USA)
  • Developer BN ImmunoTherapeutics; National Cancer Institute (USA); University of California at San Francisco
  • Class Antineoplastics; Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Prostate cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Prostate cancer

Most Recent Events

  • 01 Aug 2016 Phase-II clinical trials in Prostate cancer (Neoadjuvant therapy, Monotherapy, Combination therapy) in USA (SC) (NCT02506114)
  • 01 Jul 2016 Phase-II clinical trials in Prostate cancer (Adjuvant therapy) in USA (unspecified route) (NCT02772562)
  • 13 May 2016 Bavarian Nordic initiates enrolment in two phase II trials for Prostate cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top